Doxapram for Apnoea of Prematurity and Age 5-6 Years Neurodevelopmental Outcomes

Archive ouverte

Tréluyer, Ludovic | Zana-Taieb, Elodie | Jarreau, Pierre-Henri | Benhammou, Valérie | Kuhn, Pierre | Letouzey, Mathilde | Marchand-Martin, Laetitia | Onland, Wes | Pierrat, Véronique | Saade, Lauren | Ancel, Pierre Yves | Torchin, Héloïse

Edité par CCSD ; BMJ Publishing Group -

International audience. Objective: To assess the long-term neurodevelopmental impact of doxapram for treating apnoea of prematurity.Design: Secondary analysis of the French national cohort study EPIPAGE-2. Recruitment took place in 2011. A standardised neurodevelopmental assessment was performed at age 5-6 years. A 2:1 propensity score matching was used to control for the non-randomised assignment of doxapram treatment.Setting: Population-based cohort study.Patients: All children born before 32 weeks' gestation alive at age 5-6 years.Interventions: Blind and standardised assessment by trained neuropsychologists and paediatricians at age 5-6 years.Main outcome measures: Neurodevelopmental outcomes at age 5-6 years assessed by trained paediatricians and neuropsychologists: cerebral palsy, developmental coordination disorders, IQ and behavioural difficulties. A composite criterion for overall neurodevelopmental disabilities was built.Results: The population consisted of 2950 children; 275 (8.6%) received doxapram. Median (IQR) gestational age was 29.4 (27.6-30.9) weeks. At age 5-6 years, complete neurodevelopmental assessment was available for 60.3% (1780 of 2950) of children and partial assessment for 10.6% (314 of 2950). In the initial sample, children receiving doxapram had evidence of greater clinical severity than those not treated. Doxapram treatment was associated with overall neurodevelopmental disabilities of any severity (OR 1.43, 95% CI 1.07 to 1.92, p=0.02). Eight hundred and twenty-one children were included in the 2:1 matched sample. In this sample, perinatal characteristics of both groups were similar and doxapram treatment was not associated with overall neurodevelopmental disabilities (OR 1.09, 95% CI 0.76 to 1.57, p=0.63).Conclusions: In children born before 32 weeks' gestation, doxapram treatment for apnoea of prematurity was not associated with neurodevelopmental disabilities.

Suggestions

Du même auteur

Neurodevelopment and healthcare utilisation at age 5–6 years in bronchopulmonary dysplasia: an EPIPAGE-2 cohort study

Archive ouverte | Tréluyer, Ludovic | CCSD

International audience. Objective We aimed to study neurodevelopmental outcomes and healthcare utilisation at age 5–6 years in very preterm children with bronchopulmonary dysplasia (BPD). Design Prospective and nati...

Intraventricular Hemorrhage in Very Preterm Children: Mortality and Neurodevelopment at Age 5

Archive ouverte | Tréluyer, Ludovic | CCSD

International audience. The objectives were to describe mortality and causes of death in children with intraventricular hemorrhage (IVH) and to study neurodevelopmental outcomes. The study was a secondary analysis o...

Neurodevelopment at age 5.5 years according to Ages & Stages Questionnaire at 2 years’ corrected age in children born preterm: the EPIPAGE-2 cohort study

Archive ouverte | Charkaluk, Marie-Laure | CCSD

International audience. Objective To report neurodevelopment at age 5.5 years according to developmental delay screening with the Ages & Stages Questionnaire (ASQ) in late infancy in preterm-born children. Desig...

Chargement des enrichissements...